Article Contents ::
- 1 The Brand Name 4-EPPEDO Has Generic Salt :: EPIRUBICIN
- 2 4-EPPEDO Is From Company MIRACALUS Priced :: Rs. 2200
- 3 4-EPPEDO have EPIRUBICIN is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name 4-EPPEDO Has Generic Salt :: EPIRUBICIN
4-EPPEDO Is From Company MIRACALUS Priced :: Rs. 2200
4-EPPEDO have EPIRUBICIN is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Acute leukaemias; Lymphoma; Multiple myeloma, Breast cancer, Bladder carcinoma
Drug Dose ::
Adult: IV Acute leukaemias; Lymphoma; Multiple myeloma; Solid tumours As a single agent: 60-90 mg/m2 3-4 wkly. Max (total cumulative dose): 0.9-1 g/m2. Palliative care: 12.5-25 mg/m2 once wkly. Adjuvant treatment in axillary-node positive breast cancer Recommended starting doses: 100-120 mg/m2 as a single dose on day 1 or as 2 divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles. Intravesical Local treatment of bladder carcinoma As 0.1% soln: 50 mg/wk for 8 wk; reduce dose if chemical cystitis develops. For carcinoma in-situ: 80 mg in 50 mL wkly. For prevention of recurrence in patients who have undergone transurethral resection: 50 mg/wk for 4 wk, followed by 50 mg/mth for 11 mth; retain soln in the bladder for 1 hr during each administration.
Cardiac impairment, severe or recent MI; previous full cumulative doses of anthracyclines. Hypersensitivity; severe hepatic dysfunction. Not for intravesical use where invasive tumours have penetrated the bladder wall; urinary infections, bladder inflammation or catheterisation problems. Pregnancy, lactation.
Drug Precautions ::
Previous extensive radiotherapy, bone infiltration by tumour, severe renal and hepatic dysfunction. May cause tumor lysis syndrome or radiation recall. Elderly women >70 yr. CV disease, hypertensive cardiomyopathy; monitor hematological and cardiac function regularly. Extravasation during IV admin may result in severe local tissue necrosis. Do not give via IM/SC routes as extravasation can lead to severe local necrosis.
Drug Side Effects ::
Myelosuppression; cardiotoxicity, alopoecia; mucositis; hyperpyrexia; lethargy; amenorrhoea; nausea and vomiting; diarrhoea; fever; rash, skin changes, anorexia; anaphylaxis; photosensitivity; premature menopause; skin and nail hyperpigmentation; harmless reddish appearance of urine for 1-2 days.
Pregnancy category ::
Drug Mode of Action ::
Epirubicin, an anthracycline with cytotoxic properties. It inhibits DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs that triggers DNA cleavage by by topoisomerase II. It also inhibits DNA helicase and generates cytotoxic free radicals. Distribution: Rapidly and extensively distributed into body tissues.
Drug Interactions ::
Paclitaxel and other anthracyclines. Cimetidine, heparin. Antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs.